Dados do Trabalho

Título

Long-Term Evaluation of Post-Transplant Lymphoproliferative Disorders in Paediatric Heart Transplantation

Introdução

We sought to better define the demographics and characteristics of PTLD in a cohort of paediatric OHT patients.

Material e Método

Data was collected from the Heart Institute, Sao Paulo for all paediatric-OHT recipients from October 1992 to October 2018. Group differences between the PTLD and non-PTLD cohorts were assessed by Fisher Exact and Mann Whitney U tests. Kaplan Meier curves analysed the survival in each group.

Resultados

Data was reviewed for 202 paediatric OHT recipients. Overall 1, 5 and 10-year survival for the entire cohort was 76.5%, 68.3% and 62.9%. 24 patients (11.9%) developed PTLD at a median 3.1 years (IQR: 0.8–9.0) after OHT. Cases were evenly spread over the follow-up period, with PTLD diagnosed in 9.8% (n=137) of patients who were alive at 3 years, 15.3% (n = 78) who were alive at 5 years and 29.3% (n=41) of patients at 10 years (Figure 1).
The commonest form of PTLD was diffuse large B cell lymphoma (n=9), and most patients received rituximab with immunosuppression and chemotherapy as treatment (n=15). We identified no increased risk in mortality amongst the PTLD vs. non PTLD cohorts (p=0.221).

Discussão e Conclusões

PTLD after paediatric OHT had acceptable outcomes. However, risk factors for PTLD were not identified and warrant further investigation.

Palavras Chave

PTLD
Paediatric Heart Transplantation
Survival